4//SEC Filing
Shani Eli 4
Accession 0001209191-22-014474
CIK 0000818686other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 7:53 AM ET
Size
9.6 KB
Accession
0001209191-22-014474
Insider Transaction Report
Form 4
Shani Eli
EVP,Global Marketing&Portfolio
Transactions
- Sale
Ordinary Shares
2022-02-28$8.14/sh−5,311$43,243→ 9,091 total - Exercise/Conversion
Ordinary Shares
2022-02-28+5,311→ 14,402 total - Exercise/Conversion
Restricted Share Units
2022-02-28−5,311→ 10,623 total→ Ordinary Shares (5,311 underlying)
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.035 to $8.255, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Restricted share units were granted on February 28, 2020, with 5,311 having vested on each of February 28, 2021 and February 28, 2022, 5,311 vesting on February 28, 2023 and 5,312 vesting on February 28, 2024.
Documents
Issuer
TEVA PHARMACEUTICAL INDUSTRIES LTD
CIK 0000818686
Entity typeother
Related Parties
1- filerCIK 0001876642
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 7:53 AM ET
- Size
- 9.6 KB